Expression of adhesion molecules in malignant plasma cells in multiple myeloma: Comparison with normal plasma cells and functional significance

Blood Reviews

Volumn 11, Issue 1, 1997, Pages 28-38

  Helfrich, M H ^a   Livingston, E ^a   Franklin, I M ^b   Soutar, R L ^c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c MONKLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CYTOKINE;

ARTICLE; BONE CELL; BONE MARROW; MULTIPLE MYELOMA; OSTEOCLAST; OSTEOLYSIS; PLASMA CELL; PRIORITY JOURNAL; STROMA CELL;

EID: 0030924783     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(97)90004-7     Document Type: Article

References (89)

1. MacLennan IC, Chamnan C, Dunn J, Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Medical Research Council Working Party for Leukaemia in Adults. Lancet 1992; 339: 200-205.
2. Jensen GS, Mant MJ, Belch AJ, Berensen JR, Ruether BA, Pilarski LM. Selective expression of CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells. Blood 1991; 78: 711-719.
3. Billadeau D, Van Ness B, Kimlinger T et al. Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood 1996; 88: 289-296.
4. Caligaris-Cappio F, Gregoretti MG, Merico F et al. Bone marrow microenvironment and the progression of multiple myeloma. Leukemia and Lymphoma 1992; 8: 15-22.
5. Barlogie B, Epstein J, Selvanayagam P, Alexanian R. Plasma cell myeloma: new biological insights and advances in therapy. Blood 1989; 73: 865-879.
6. Hemler ME. VLA proteins in the integrin family: structure, functions and their role on leukocytes. Annu Rev Immunol 1990; 8: 265-400.
7. Hynes RO. Integrins: versatility, modulation, and signalling in cell adhesion. Cell 1992; 69: 11-25.
8. Frenette P, Wagner D. Adhesion molecules. I. N Engl J Med 1996; 443: 1526-1529.
9. Frenette P, Wagner D. Adhesion molecules. II. N Engl J Med 1996; 335: 43-45.
10. Horton MA. Vitronectin receptor: tissue specific expression or adaptation to culture? Int J Exp Pathol 1990; 71: 741-759.
11. Springer TA. Adhesion receptor of the immune system. Nature 1990; 346: 425-433.
12. Pigott R, Power C. The adhesion molecule factsbook. London: Academic Press, 1993.
13. Bernfield M, Hinkes MT, Gallo RL. Developmental expression of the syndecans: possible function and regulation. Development 1993; (Suppl): 205-212.
14. Elenius K, Jalkanen M. Function of the syndecans - a family of cell surface proteoglycans. J Cell Sci 1994; 107: 2975-2982.
15. Wijdenes J, Vooijs WC, Clément C et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 1996; 94: 318-323.
16. Jalkanen S, Bartgatze RF, de los Toyos J, Butcher EC. Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95 kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells. J Cell Biol 1987; 105: 983-990.
17. Carter WG, Wayner EA. Characterisation of the class III collagen receptor, a phosphorylated, transmembrane glycoprotein expressed in nucleated human cells. J Biol Chem 1988; 263: 4193-4201.
18. Jalkanen S, Jalkanen M. Lymphocyte CD44 binds the COOH terminal heparin binding domain of fibronectin. J Cell Biol 1992; 116:817-825.
19. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptorligand interaction between CD44 and osteopontin (Eta-1). Science 1996; 271: 509-512.
20. MacLennan ICM, Hardie DL, Ball J, Drew M. Antibody-secreting cells and their origins. In: Malpas JS, Bergsagel DE, Kyle RA, eds. Myeloma: Biology and Management. Oxford: Oxford University Press, 1995: 30-49.
21. Owen M. Marrow stromal cells. J Cell Sci 1988; 10 (suppl): 63-76.
22. Kincade PW, Lee G, Pietrangeli CE, Hayashi S, Gimble JM. Cells and molecules that regulate B lymphopoeisis in bone marrow. Annu Rev Immunol 1989: 7: 111-143.
23. Dorshkind K. Regulation of hemopoiesis by bone marrow stromal cells and their products. Annu Rev Immunol 1990; 8: 111-137.
24. Teixido J, Hemler ME, Greenberger JS, Anklesaria P. J Clin Invest 1992; 90: 358-367.
25. Ryan DH, Nuccie BL, Abboud CM, Winslow JM. Vascular cell adhesion molecule-1 and the integrin VLA-4 mediate adhesion of human B cell precursors to cultured bone marrow adherent cells. J Clin Invest 1991; 88: 995-1004.
26. Dittel BN, McCarthy JB, Wayner EA, LeBien TW. Regulation of human B-cell precursor adhesion to bone marrow stromal cells by cytokines that exert opposing effects on the expression of vascular cell adhesion molecule-1 (VCAM-1). Blood 1993; 81: 2272-2282.
27. Patrick CW Jr, Harinder SJ, Lee S, Schmalstieg FC, McIntire LV Heterotypic adherence between human B-lymphoblastic and pre-B-lymphoblastic cells and marrow stromal cells is a biphasic event: integrin very late antigen 4α mediates only the early phase of the heterotypic adhesion. Blood 1995; 85: 168-178.
28. Dittel BN, LeBien TW. Reduced expression of vascular cell adhesion molecule-1 on bone marrow stromal cells isolated from marrow transplant recipients correlates with a reduced capacity to support human B lymphopoiesis in vitro. Blood 1995; 86: 2833-2841.
29. Erle DJ, Briskin MJ, Butcher EC, Garcio-Pardo A, Lazarovits AI, Tidswell M. Expression and function of the MAdCAM-1 receptor, integrin α4β7. on human leukocytes. J Immunol 1994; 153: 517-528.
30. Briskin MJ, Rott L, Butcher EC. Structural requirements for mucosal vascular addressin binding to its lymphocyte receptor α4β7. J Immunol 1996; 156: 719-726.
31. Roldan E, Brieva JA. Terminal differentiation of human bone marrow cells capable of spontaneous and high rate immunoglobulin secretion: role of bone marrow stromal cells and interleukin 6. Eur J Immunol 1991; 21: 2671-2677.
32. Roldan E, Garcia-Pardo A, Brieva JA. VLA-4 fibronectin interaction is required for the terminal differentiation of human bone marrow cells capable of spontaneous and high rate immunoglobulin secretion. J Exp Med 1992; 175: 1739-1747.
33. Van Riet I, De Greef C, Del Favero H, Demanet C, Van Camp B. Production of fibronectin and adherence to fibronectin by human myeloma cell lines. Br J Haematol 1994; 87: 258-265.
34. Anderson KC, Park EK, Bates MP. Antigens on human plasma cells identified by monoclonal antibodies. J Immunol 1983; 130: 1132-1138.
35. Anderson KC, Bates MP, Slaughenhoupt B, Schlossman SF, Nadler LM. A monoclonal antibody with reactivity restricted to normal and neoplastic plasma cells. J Immunol 1984; 132: 3172-3179.
36. Van Camp B, Durie BGM, Spier C et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen CD 56 (NKH-1, Leu 19). Blood 1990; 76: 377-382.
37. Leo R, Boeker M, Peest D et al. Multiparameter analysis of normal and malignant human plasma cells: CD38++, CD56+, CD54+, clg+ is the common phenotype of myeloma cells. Ann Hematol 1992; 64: 132-139.
38. Harada H, Kawano MM, Huang N et al. Phenotypic difference of normal plasma cells from mature plasma cells. Blood 1993; 81: 2658-2663.
39. Portier M, Rajzbaum G, Zhang X-G et al. In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma. Eur J Immunol 1991; 21: 1759-1762.
40. Borset M, Helseth E, Naume B, Waage A. Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation. Br J Haematol 1993; 85: 446-451.
41. Pellat Deceunynck C, Bataille R, Robillard N et al. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood 1994; 84: 2597-2603.
42. Herriot R, Soutar RL, Milton JI. Use of B-B4 monoclonal antibody and ferrous microbeads to purify plasma cells in myeloma. Br J Haematol 1995; 89 (suppl 1): 304.
43. Pellat-Deceunynck C, Barillé S, Puthier D et al. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumour spreading, and immortalization. Cancer Res 1995; 55: 3647-3653.
44. Huang N, Kawano MM, Mahmoud MS et al. Expression of CD21 antigen on myeloma cells and its involvement in their adhesion to bone marrow stromal cells. Blood 1995; 12: 3704-3712.
45. Van Riet I, De Waele M, Remels L, Lacor P, Schots R, Van Camp B. Expression of cytoadhesion molecules (CD 56, CD54, CD18, CD29) by myeloma cells. Br J Haematol 1991; 79: 421-427.
46. Barker HF, Ball J, Drew M, Hamilton MS, Franklin IM. The role of adhesion molecules in multiple myeloma. Leukemia and Lymphoma 1992; 81: 331-335.
47. Van Riet I, Van Camp B. The involvement of adhesion molecules in the biology of multiple myeloma. Leukemia and Lymphoma 1993; 9: 441-452.
48. Kawano MM, Huang N, Harada H et al. Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood 1993; 82: 564-570.
49. Pellat-Deceunynck C, Bataille R, Robillard N et al. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood 1994; 84: 2597-2603.
50. Ashmann EJM, Lokhorst HM, Dekker AW, Bloem AC. Lymphocyte function-associated antigen-1 expression on plasma cells correlates with tumour growth in multiple myeloma. Blood 1992; 79: 2068-2075.
51. Bartl R, Frisch B, Wilmanns W. Morphology of multiple myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, eds. Myeloma: Biology and Management. Oxford: Oxford University Press, 1995: 82-123.
52. Van Riet I, Bakkus M, De Greef C, Faid L, Van Camp B. Homing mechanisms in the etiopathogenesis of multiple myeloma. Stem Cells 1995; 13 (suppl 2): 22-27.
53. Epstein J, Hoover R, Kornbluth J, Barlogie B. Biological aspects of multiple myeloma. In: Mandelli F, ed. Multiple Myeloma. Baillière's Clinical Haematology. London: Baillière Tindall, 1995; 8(4): 721-734.
54. Bakkus MHC, Van Riet I, Van Camp B, Thielemans K. Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br J Haematol 1994; 87: 68-74.
55. Billadeau D, Quam L, Thomas W et al. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Br J Haematol 1992; 80: 1818-1824.
56. Pilarski LM, Jensen GS. Monoclonal circulating B cells in multiple myeloma: a continously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules. In: Barlogie B, ed. Multiple Myeloma. Hematol Oncol Clin North Am. Philadelphia, PA: WB Saunders, 1992; 6: 297-322.
57. Uchiyama H, Barut BA, Chauhan D, Cannistra SA, Anderson KC. Characterization of adhesion molecules on human myeloma cell lines. Blood 1992; 80: 2306-2314.
58. Livingston E, Gill D, Soutar R, Ralston S, Helfrich M. Adhesion of myeloma cells to extracellular matrix proteins. Bone 1996; 19: 685.
59. Livingston E, Gill D, Soutar R, Herriot R, Ralston S, Helfrich M. Malignant plasma cells in patients with myeloma express high levels of α4β7 integrin. Bone 1995; 17: 591.
60. Jensen GS, Belch AR, Mant MJ, Ruether BA, Pilarski LM. Expression of multiple adhesion molecules on circulating monoclonal B cells in myeloma. Current Topics Microbiol Immunol 1991; 182: 187-193.
61. Jensen GS, Belch AR, Mant MJ, Ruether BA, Yacyshyn BR, Pilarski LM. Expression of multiple β1 integrins on circulating monoclonal B cells in patients with multiple myeloma. Am J Hematol 1993; 43: 29-36.
62. Kim I, Uchiyama H, Chauhan D, Anderson KC. Cell surface expression and functional significance of adhesion molecules on human myeloma-derived cell lines. Br J Haematol 1994; 87: 483-493.
63. Picker LJ, Medeiros LJ, Weiss LM, Warnke RA, Butcher EC. Expression of lymphocyte homing receptor antigen in non-Hodgkin's lymphoma. Am J Pathol 1988; 130: 496-504.
64. Stauder R, Greil R, Schulz TF et al. Expression of leucocyte function associated antigen-1 and 7F7-antigen, an adhesion molecule related to intercellular adhesion molecule-1 (ICAM-1) in non-Hodgkin's lymphoma and leukaemias: possible influence on growth pattern and leukaemic behaviour. Clin Exp Immunol 1989; 77: 234-238.
65. Drach J, Gattringer C, Huber H. Expression of the neural cell adhesion molecule (CD 56) by human myeloma cells. Clin Exp Immunol 1991; 83: 418-422.
66. Pellat-Deceunynck C, Amiot M, Robillard N, Wijdenes J, Bataille R. CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation. Cancer Res 1996; 56: 1909-1916.
67. Ridley RC, Xiao H, Hata H, Woodliff J, Epstein J, Sanderson RD. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood 1993; 81: 767-774.
68. Hamilton MS, Ball J, Bromidge E, Franklin IM. Surface antigen expression of human neoplastic plasma cells includes molecules associated with lymphocyte recirculation and adhesion. Br J Haematol 1991; 78: 60-65.
69. Medical Research Council Working Party for Therapeutic Trials in Leukaemia. Myelomatosis: comparison of melphalan and cyclophosphamide therapy. Br Med J 1971; 1: 640-641.
70. Medical Research Council Working Party on Leukaemia in Adults. Report on the second myelomatosis trial after five years of follow up. Br J Cancer 1980; 42: 813-822.
71. Medical Research Council Working Party on Leukaemia in Adults. Treatment comparisons in the third MRC myelomatosis trial. Br J Cancer 1980; 42: 823-830.
72. Medical Research Council Working Party on Leukaemia in Adults. Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Br J Cancer 1985; 52: 153-158.
73. Kyle R. Diagnostic criteria of multiple myeloma. In: Barlogie B, ed. Multiple Myeloma. Hematol Oncol Clin North Am Philadelphia, PA: WB Saunders, 1992; 6: 347-358.
74. Kyle RA. Monoclonal gammopathy of undetermined significance. Blood Rev 1994; 8: 135-141.
75. Barillé S, Collette M, Bataille R, Amiot M. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood 1995; 86: 3151-3159.
76. Kyle RA. Plasma cell proliferative disorders. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, eds. Hematology: Basic Principles and Practice. New York: Churchill Livingstone, 1991: 1021-1038.
77. Sanfructuoso C, Caballero MD, Garcia-Sanz R, Vidriales B, Vazquez L, San Miguel JF. Relapse of multiple myeloma in extramedullary sites after autologous bone marrow transplantation. Eur J Haematol 1996; 56: 181-183.
78. Klein B. Cytokine, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma. In: Kyle RA, ed. The Gammopathies. Seminars in Hematology. Philadelphia, PA: WB Saunders, 1995; 32: 4-19.
79. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates IL-6 secretion. Blood 1993; 82: 3712-3720.
80. Lokhorst HM, Lamme T, de Smet M et al. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood 1994; 84: 2269-2277.
81. Chauhan D, Uchiyama H, Akbarali Y et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood 1996; 87: 1104-1112.
82. Kyle RA. Why better prognostic factors for myeloma are needed. Blood 1994; 83: 1713-1716.
83. Jalkanen S, Joensuu H, Klemi P. Prognostic value of lymphocyte homing receptor and S-phase fraction in Non-Hodgkin's lymphoma. Blood 1990; 75: 1549-1556.
84. Medeiros LJ, Weiss LM, Picker LJ. Expression of LFA-1 in non-Hodgkin's lymphoma. Cancer 1989; 63: 255-259.
85. Clayberger C, Medeiros LJ, Link MP et al. Absence of cell surface LFA-1 as a mechanism of escape from immunosurveillance. Lancet 1987; 2: 533-536.
86. Bloemen PGM, Hendricks PAJ, van Bloois L et al. Adhesion molecules: a new target for immunoliposome-mediated drug delivery. FEBS Lett 1995; 357: 140-144.
87. Jabukowski A, Newman Ehrenfels BN, Blake Pepinsky R, Burkly LC Vascular cell adhesion molecule-Ig fusion protein selectively targets activated α4-integrin receptors in vivo. J Immunol 1995; 155: 938-946.
88. Matsuura N, Puzon-McLaughlin W, Irie A, Morikawa Y, Kakudo K, Takada Y. Induction of experimental bone metastasis in mice by transfection of integrin α4β1 into tumor cells. Am J Pathol 1996; 148: 55-61.
89. Pellat-Deceunynck C, Amiot M, Bataille R et al. Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after. Blood 1995; 86: 4001-4002.